Align Technology (NASDAQ:ALGN) been upgraded to outperform from market perform by Leerink Partners. Calling Align ...

Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being ...

Research analysts at Leerink Partnrs lowered their Q4 2024 earnings per share estimates for Laboratory Co. of Amer ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to ...

In recent trading, Tenaya Therapeutics Inc (TNYA) stock price has shown some volatility, fluctuating -0.70% over the last five trades a ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...